These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19641233)

  • 21. Tryptophan dendrimers that inhibit HIV replication, prevent virus entry and bind to the HIV envelope glycoproteins gp120 and gp41.
    Rivero-Buceta E; Doyagüez EG; Colomer I; Quesada E; Mathys L; Noppen S; Liekens S; Camarasa MJ; Pérez-Pérez MJ; Balzarini J; San-Félix A
    Eur J Med Chem; 2015 Dec; 106():34-43. PubMed ID: 26513643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide.
    Forssmann WG; The YH; Stoll M; Adermann K; Albrecht U; Tillmann HC; Barlos K; Busmann A; Canales-Mayordomo A; Giménez-Gallego G; Hirsch J; Jiménez-Barbero J; Meyer-Olson D; Münch J; Pérez-Castells J; Ständker L; Kirchhoff F; Schmidt RE
    Sci Transl Med; 2010 Dec; 2(63):63re3. PubMed ID: 21178138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity.
    Chong H; Qiu Z; Su Y; He Y
    J Med Chem; 2015 Aug; 58(16):6378-88. PubMed ID: 26256053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
    McElrath MJ; Ballweber L; Terker A; Kreger A; Sakchalathorn P; Robinson B; Fialkow M; Lentz G; Hladik F
    Antimicrob Agents Chemother; 2010 Feb; 54(2):763-72. PubMed ID: 19949052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
    van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
    Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
    Gómara MJ; Sánchez-Merino V; Paús A; Merino-Mansilla A; Gatell JM; Yuste E; Haro I
    Biochim Biophys Acta; 2016 Jun; 1860(6):1139-48. PubMed ID: 26905802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).
    Jenabian MA; Saïdi H; Charpentier C; Van Herrewege Y; Son JC; Schols D; Balzarini J; Vanham G; Bélec L;
    J Antimicrob Chemother; 2009 Dec; 64(6):1192-5. PubMed ID: 19875507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
    Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
    J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV entry inhibitors: mechanisms of action and resistance pathways.
    Briz V; Poveda E; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):619-27. PubMed ID: 16464888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC; Doms RW
    Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-20--a fusion drug, first of several to come.
    TreatmentUpdate; 1998 Dec; 10(10):2. PubMed ID: 11366015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the sticky fingers of HIV-1.
    Blumenthal R; Dimitrov DS
    Cell; 2007 Apr; 129(2):243-5. PubMed ID: 17448985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.
    Curreli F; Haque K; Xie L; Qiu Q; Xu J; Yong W; Tong X; Debnath AK
    Bioorg Med Chem; 2015 Dec; 23(24):7618-28. PubMed ID: 26602829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
    Barretina J; Blanco J; Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
    Antivir Ther; 2003 Apr; 8(2):155-61. PubMed ID: 12741628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.
    Goffinet C; Allespach I; Keppler OT
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):1015-20. PubMed ID: 17209012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.
    Ashkenazi A; Wexler-Cohen Y; Shai Y
    Biochim Biophys Acta; 2011 Oct; 1808(10):2352-8. PubMed ID: 21762676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.